A

Alumis Inc.
D

ALMS

19.050
USD
-1.32
(-6.48%)
مغلق
حجم التداول
55,566
الربح لكل سهم
-3
العائد الربحي
-
P/E
-11
حجم السوق
2,428,722,219
المقالات
المزيد

العنوان: Alumis Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005,a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.